Coherus Oncology (FRA:8C5) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8C5 Coherus Oncology Inc FRA:8C5
57 GF Score
Price €1.14
GF Value €0.89
! 7 Warning Signs
View Full Analysis

What is Coherus Oncology 5-Year EBITDA Growth Rate?

Coherus Oncology FRA:8C5 +1.96% 57 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 57/100 and a GF Value™ of €0.89. The stock has 7 warning signs investors should review.

Coherus Oncology's EBITDA per Share for the three months ended in Jun. 2026 was €-0.17.

During the past 3 years, the average EBITDA Per Share Growth Rate was 23.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Coherus Oncology was 25.10% per year. The lowest was -51.20% per year. And the median was 20.40% per year.

Coherus Oncology  (FRA:8C5) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Coherus Oncology 5-Year EBITDA Growth Rate Related Terms

FRA:8C5 vs VYGR, KROS, DTIL: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Coherus Oncology's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's 5-Year EBITDA Growth Rate falls into.


FRA:8C5
57GF Score
Coherus Oncology Inc FRA:8C5
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coherus Oncology 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Coherus Oncology (FRA:8C5) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Coherus Oncology and its competitors.
Is Coherus Oncology's 5-Year EBITDA Growth Rate too high?
Coherus Oncology's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Coherus Oncology has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's 5-Year EBITDA Growth Rate compare to VYGR and KROS?
Coherus Oncology's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Coherus Oncology and its competitors. Coherus Oncology's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Coherus Oncology (FRA:8C5) has a current 5-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is €0.89, compared to a current price of €1.14 — trading 28.4% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Coherus Oncology's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.14 is trading 28.4% above its estimated GF Value™ of €0.89.

Key valuation signals for FRA:8C5:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: €0.89 vs. price of €1.14 (28.4% above fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
57GF Score

Get the complete analysis for FRA:8C5

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.14
Price
€0.89
GF Value